CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review AIM2-driven inflammasome activation in heart failure The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure

Clinical TrialNov. 17, 2019

JOURNAL:Circulation. Article Link

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial

MN Kosiborod, PJhund, KF Docherty et al. Keywords: dapagliflozin; HFrEF; quality of life; cardiovascular outcomes

FULL TEXT PDF